Comparison of Outcomes Using Radiotherapy or Brachytherapy after Resection of Primary Adenoid Cystic Carcinoma in Oral and Maxillofacial Regions.

C. Li,S. M. Liu,L. Zheng,M. W. Huang,Y. Shi,X. M. Lv,J. G. Zhang,X. Peng,J. Zhang
DOI: https://doi.org/10.1016/j.brachy.2020.08.013
IF: 2.441
2021-01-01
Brachytherapy
Abstract:We wished to investigate the outcome of surgery combined with external-beam radiotherapy (EBRT) or brachytherapy (I-125 seeds) for the treatment of primary adenoid cystic carcinoma (ACC) of the oral and maxillofacial region. Data of patients with primary ACC were reviewed retrospectively. Patients were divided into EBRT and brachytherapy groups. Wide tumor excision was done to achieve negative margins. Standard radiotherapy in the EBRT group was 60 Gy. A treatment-planning system was used to create implantation plans with a prescribed dose of 60-120 Gy and I-125 seeds were implanted postoperatively. Kaplan-Meier method and log-rank tests were used to analyze local control and survival. The median duration of followup was 66.1 and 46.8 months for the EBRT group and brachytherapy group, respectively. There was no significant difference in local control, control of metastasis to regional lymph nodes, or control of distant metastasis between the two groups. There was no significant difference in overall survival, disease-specific survival, or disease-free survival in the two groups at 3 years and 5 years. The prevalence of complications in the brachytherapy group was lower than that in the EBRT group. Both methods elicited good treatment effects, but the prevalence of adverse events was lower in the brachytherapy group. (c) 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?